Effect of BIBF 1120 on reversal of ABCB1-mediated multidrug resistance | Zendy

Qing-feng Xiang | Zendy; Fang Wang | Zendy; XiaoDong Su | Zendy; Yongju Liang | Zendy; Li-Sheng Zheng | Zendy; Yanjun Mi | Zendy; Weiqiang Chen | Zendy; Liwu Fu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effect of BIBF 1120 on reversal of ABCB1-mediated multidrug resistance

Author(s) -

Qing-feng Xiang,

Fang Wang,

XiaoDong Su,

Yongju Liang,

Li-Sheng Zheng,

Yanjun Mi,

Weiqiang Chen,

Liwu Fu

Publication year - 2011

Publication title -

cellular oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.698

H-Index - 40

eISSN - 2211-3436

pISSN - 2211-3428

DOI - 10.1007/s13402-010-0003-7

Subject(s) - abcc1 , multiple drug resistance , tyrosine kinase , abcg2 , fibroblast growth factor receptor , pharmacology , growth factor receptor , tyrosine kinase inhibitor , biology , platelet derived growth factor receptor , receptor , chemistry , growth factor , atp binding cassette transporter , biochemistry , fibroblast growth factor , cancer , transporter , genetics , gene , antibiotics

The overexpression of ATP-binding cassette (ABC) transporters is one of the main causes of multi-drug resistance (MDR) which represents a major obstacle to the success of cancer chemotherapy. In this study, we examined the effect of BIBF 1120, an inhibitor of vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors (PDGFRs) and fibroblast growth factor receptors (FGFRs) tyrosine kinases, on the reversal of multidrug resistance in vitro.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research